Galectin (Gal)‐1 demonstrates both pro‐ and anti‐inflammatory features that are not fully understood and has been shown to interact with MUC16.28 Gal‐1 agonists are under development as anti‐inflammatories but there are no clinical studies at the moment in chronic lung disease. Here, GAL is linked to chronic lung disease.